Indoleamine 2, 3-dioxygenase 1 (IDO): A mediator of immunoresistance in adults with brain cancer treated with immunomodulatory therapy

Lijie Zhai; Erik Ladomersky; Kristen L. Lauing; Lakshmi Bollu; April Bell; Miri Kim; Erik Rabin; Derek A. Wainwright

doi:10.1016/B978-0-12-819755-4.00006-0

Indoleamine 2, 3-dioxygenase 1 (IDO): A mediator of immunoresistance in adults with brain cancer treated with immunomodulatory therapy

Lijie Zhai, Erik Ladomersky, Kristen L. Lauing, Lakshmi Bollu, April Bell, Miri Kim, Erik Rabin, Derek A. Wainwright

Neurological Surgery

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Indoleamine 2, 3-dioxygenase 1 (IDO; IDO1) is expressed in > FoxP3⁺). Since IDO is canonically characterized as a rate-limiting enzyme that metabolizes the essential amino acid, tryptophan (Trp), into kynurenine (Kyn), the depletion of Trp and/or accumulation of Kyn has been the presumed mechanism of how IDO suppresses the anti-GBM immune response. However, our work has challenged this hypothesis, and here we provide a comprehensive update of IDO effects in adults with GBM.

Original language	English (US)
Title of host publication	Immunotherapeutic Strategies for the Treatment of Glioma
Publisher	Elsevier
Pages	127-151
Number of pages	25
ISBN (Electronic)	9780128197554
DOIs	https://doi.org/10.1016/B978-0-12-819755-4.00006-0
State	Published - Jan 1 2021

Keywords

Age
Glioblastoma
Glioma
IDO1
Immunosuppression
Immunotherapy
Kynurenine
Metabolism
Treg

ASJC Scopus subject areas

General Agricultural and Biological Sciences
General Biochemistry, Genetics and Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-12-819755-4.00006-0

Cite this

Zhai, L., Ladomersky, E., Lauing, K. L., Bollu, L., Bell, A., Kim, M., Rabin, E., & Wainwright, D. A. (2021). Indoleamine 2, 3-dioxygenase 1 (IDO): A mediator of immunoresistance in adults with brain cancer treated with immunomodulatory therapy. In Immunotherapeutic Strategies for the Treatment of Glioma (pp. 127-151). Elsevier. https://doi.org/10.1016/B978-0-12-819755-4.00006-0

@inbook{2c9bd69a6d6a4ca1827442222ee670d9,

title = "Indoleamine 2, 3-dioxygenase 1 (IDO): A mediator of immunoresistance in adults with brain cancer treated with immunomodulatory therapy",

abstract = "Indoleamine 2, 3-dioxygenase 1 (IDO; IDO1) is expressed in > FoxP3+). Since IDO is canonically characterized as a rate-limiting enzyme that metabolizes the essential amino acid, tryptophan (Trp), into kynurenine (Kyn), the depletion of Trp and/or accumulation of Kyn has been the presumed mechanism of how IDO suppresses the anti-GBM immune response. However, our work has challenged this hypothesis, and here we provide a comprehensive update of IDO effects in adults with GBM.",

keywords = "Age, Glioblastoma, Glioma, IDO1, Immunosuppression, Immunotherapy, Kynurenine, Metabolism, Treg",

author = "Lijie Zhai and Erik Ladomersky and Lauing, {Kristen L.} and Lakshmi Bollu and April Bell and Miri Kim and Erik Rabin and Wainwright, {Derek A.}",

year = "2021",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-819755-4.00006-0",

language = "English (US)",

pages = "127--151",

booktitle = "Immunotherapeutic Strategies for the Treatment of Glioma",

publisher = "Elsevier",

}

TY - CHAP

T1 - Indoleamine 2, 3-dioxygenase 1 (IDO)

T2 - A mediator of immunoresistance in adults with brain cancer treated with immunomodulatory therapy

AU - Zhai, Lijie

AU - Ladomersky, Erik

AU - Lauing, Kristen L.

AU - Bollu, Lakshmi

AU - Bell, April

AU - Kim, Miri

AU - Rabin, Erik

AU - Wainwright, Derek A.

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Indoleamine 2, 3-dioxygenase 1 (IDO; IDO1) is expressed in > FoxP3+). Since IDO is canonically characterized as a rate-limiting enzyme that metabolizes the essential amino acid, tryptophan (Trp), into kynurenine (Kyn), the depletion of Trp and/or accumulation of Kyn has been the presumed mechanism of how IDO suppresses the anti-GBM immune response. However, our work has challenged this hypothesis, and here we provide a comprehensive update of IDO effects in adults with GBM.

AB - Indoleamine 2, 3-dioxygenase 1 (IDO; IDO1) is expressed in > FoxP3+). Since IDO is canonically characterized as a rate-limiting enzyme that metabolizes the essential amino acid, tryptophan (Trp), into kynurenine (Kyn), the depletion of Trp and/or accumulation of Kyn has been the presumed mechanism of how IDO suppresses the anti-GBM immune response. However, our work has challenged this hypothesis, and here we provide a comprehensive update of IDO effects in adults with GBM.

KW - Age

KW - Glioblastoma

KW - Glioma

KW - IDO1

KW - Immunosuppression

KW - Immunotherapy

KW - Kynurenine

KW - Metabolism

KW - Treg

UR - http://www.scopus.com/inward/record.url?scp=85125974357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125974357&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-819755-4.00006-0

DO - 10.1016/B978-0-12-819755-4.00006-0

M3 - Chapter

AN - SCOPUS:85125974357

SP - 127

EP - 151

BT - Immunotherapeutic Strategies for the Treatment of Glioma

PB - Elsevier

ER -

Indoleamine 2, 3-dioxygenase 1 (IDO): A mediator of immunoresistance in adults with brain cancer treated with immunomodulatory therapy

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this